Clinical Trials Browser

Phase 1 × tazemetostat × Gastrointestinal × Clear all

NCT03217253 2020-02-07

Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction

Phase 1 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasm Metastasis